Our recent activity
Asabys Partners da entrada al FEI y eleva su primer fondo a 117 millones
Ona Therapeutics, a portfolio company of Asabys Partners and Alta Life Sciences, appoints Dr. Antoine Yver as Chair of the Board to accelerate its ADC programs towards clinical development
Ona Therapeutics, a portfolio company of Asabys Partners and Alta Life Sciences, appoints Dr. Antoine Yver as Chair of the Board to accelerate its ADC programs towards clinical development
• Brings over 35 years of oncology drug development experience, including senior executive leadership roles at AstraZeneca and Daiichi Sankyo • Led the development and approval of multiple breakthrough medicines…
AltamarCAM and Asabys agree to integrate Aliath, their life sciences unit, into Asabys
AltamarCAM and Asabys agree to integrate Aliath, their life sciences unit, into Asabys
READ THIS NEWS IN SPANISH The resulting team will manage over €400M in investments in biotechnology and medical technologies. Management of the Alta Life Sciences Spain I FCR fund will…
Asabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financing to Accelerate Commercialization of Colovac®
Asabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financing to Accelerate Commercialization of Colovac®
READ THIS NEWS IN SPANISH Asabys joins SafeHeal’s global investor syndicate, which includes Sofinnova, Solar Eclipse and a Leading Multinational Life Sciences Corporation, bringing additional resources and strategic expertise to…